Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025;21(6):445-470.
doi: 10.2174/0115734064329573240823113924.

Unveiling the Anti-cancer Potential of Oxadiazole Derivatives: A Comprehensive Exploration of Structure-Activity Relationships and Chemico-Biological Insights

Affiliations
Review

Unveiling the Anti-cancer Potential of Oxadiazole Derivatives: A Comprehensive Exploration of Structure-Activity Relationships and Chemico-Biological Insights

Sai Satyaprakash Mishra et al. Med Chem. 2025.

Abstract

Background: Oxadiazole derivatives have shown significant potential as anti-cancer agents with low μM potencies. Some examples of drugs in this class include Raltegravir, Zibotentan, Setileuton (MK-0633), Nesapidil, Furamizole, and Tidazosin. The presence of the oxadiazole nucleus in Raltegravir exemplifies its importance in drug development, showcasing how specific structural motifs like oxadiazole can be strategically incorporated into molecules to achieve desired therapeutic effects. A large number of researchers across the globe have already developed and reported many oxadiazoles as potential anti-cancer medicines.

Objective: Therefore, we tried to discuss the anti-cancer potentials of oxadiazole derivatives reported between 2019 and 2023. The design strategies, structure-activity relationship (SAR), and protein- inhibitor interactions of potential compounds on different targets have to be identified to help the medicinal chemists design new drug-likeness oxadiazole molecules for anti-cancer therapy. Similarly, the ADMET profiles of potential oxadiazoles using the in silico SwissADME tool have to be studied.

Results: We have highlighted the recently reported most potent oxadiazole derivatives as well as their hybrid compounds. The SAR study revealed that oxadiazole-linked pyridine, indazole, thiadiazine, quinoxaline, thiazolidine, indeno-pyrazole, thiophene, piperidine, benzimidazole, triazole, and sulphonamide showcased promising anti-cancer action. The chemico-biological interactions of potential oxadiazole compounds suggest good interactions with different amino acid residues that make them possible candidates for developing novel and effective anti-cancer therapies. Similarly, the in silico ADMET report suggested favourable physicochemical, pharmacokinetic, and druglikeness properties of potential oxadiazole compounds.

Conclusion: Overall, these results will prove to be a helpful and vital tool for medicinal chemists investigating and working with oxadiazoles for anti-cancer action.

Keywords: ADMET.; Oxadiazole; anti-cancer; chemico-biological interactions; pharmacokinetic; structure-activity relationship.

PubMed Disclaimer

References

    1. Gour V.K.; Yahya S.; Shahar Yar M.; Unveiling the chemistry of 1,3,4‐oxadiazoles and thiadiazols: A comprehensive review. Arch Pharm (Weinheim) 2024,357(1),2300328 - DOI - PubMed
    1. Desai N.; Monapara J.; Jethawa A.; Khedkar V.; Shingate B.; Oxadiazole: A highly versatile scaffold in drug discovery. Arch Pharm (Weinheim) 2022,355(9),2200123 - DOI - PubMed
    1. Devi K.; Rao A.S.; Prasad R.; Raju K.; Mounika D.G.; Synthesis, anticancer and antiviral activity studies of 1,3,4-oxadiazoles: A review. Asian J Chem 2022,34(3),473-486 - DOI
    1. Ahsan M.J.; 1,3,4-oxadiazole containing compounds as therapeutic targets for cancer therapy. Mini Rev Med Chem 2022,22(1),164-197 - DOI - PubMed
    1. Kumar G.; Kumar R.; Mazumder A.; 1,3,4-oxadiazoles as anticancer agents: A review. Rec Patents Anticanc Drug Discov 2023,19(3),257-267 - DOI - PubMed

MeSH terms

LinkOut - more resources